Overview
Hertraz (Trastuzumab) 440 mg is a monoclonal antibody used in the treatment of HER2-positive breast cancer and metastatic gastric cancer. It specifically targets the HER2 receptor, a protein found in high levels on some cancer cells, and works by inhibiting cell proliferation and promoting immune-mediated destruction of tumor cells. Hertraz is administered via intravenous infusion under the supervision of an oncologist.





